Genetic mechanisms of resistance to NRTI and NNRTI

HIV Clinical Trials

Volumn 3, Issue 3, 2002, Pages 237-248

  Soriano, Vincent ^a   de Mendoza, Carmen ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Drug resistance; HIV; NAMs; Nonnucleoside analogues; Nucleoside analogs; Pyrophosphorolysis

Indexed keywords

ABACAVIR; ADEFOVIR; COMPLEMENTARY DNA; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GAG PROTEIN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

DRUG BINDING; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRION; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 0036299468     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/06DD-UN4D-9AW2-RLBY     Document Type: Review

References (114)

1. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
2. Viruses at the edge of adaptation
3. RNA virus mutations and fitness for survival
4. Dynamics of HIV pathogenesis and treatment
5. Pol gene quasispecies of HIV: Mutations associated with drug resistance in virus from patients undergoing no drug therapy
6. Nevirapine-resistant HIV: Kinetics of replication and estimated prevalence in untreated patients
7. In vivo sequence diversity of the protease of HIV-1: Presence of protease inhibitor-resistant variants in untreated subjects
8. Analysis of pol gene heterogeneity, viral quasispecies and drug resistance in individuals infected with group O strains of HIV type 1
9. Introduction of drug resistance testing in clinical practice
10. Multiple mutations in HIV-1 RT confer high-level resistance to AZT
11. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues
12. A family of insertion mutations between codons 67 and 70 of HIV type 1 RT confer multinucleoside analog resistance
13. Replicative fitness of protease inhibitor-resistant mutants of HIV type 1
14. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
15. Nucleoside reverse transcriptase inhibitor resistance
16. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 RT
17. Resistance to nucleoside analogue reverse transcriptase inhibitors mediated by HIV type 1 p6 protein
18. Ordered appearance of zidovudine resistance mutations during treatment of 18 HIV-positive subjects
19. Switch to unusual amino acids at codon 215 of the HIV-1 RT gene in seroconvertors infected with zidovudine-resistant variants
20. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
21. Drug resistance and heterogeneous long-term virologic responses of HIV-infected subjects to zidovudine and didanosine combination therapy. The ACTG 143 Virology Team
22. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
23. HIV-1 drug susceptibility during AZT monotherapy compared with AZT plus ddl or AZT plus ddC combination therapy
24. Genotypic and phenotypic analysis of HIV-1 isolates from patients on prolonged stavudine therapy
25. Lack of emergence of genotypic resistance to stavudine after two years of monotherapy
26. Emergence of zidovudine and multidrug resistance mutations in the HIV-1 RT gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
27. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
28. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
29. Comparison of genotypic and phenotypic resistance patterns of HIV-1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
30. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
31. Resistance profile of the HIV-1 RT inhibitor abacavir (1592U89) after monotherapy and combination therapy
32. HIV-1 RT genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
33. HIV-1 RT genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years
34. Prevalence and clinical significance of zidovudine resistance mutations in HIV isolated from patients after long-term zidovudine treatment. ACTG 116B/117
35. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
36. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance
37. NRTI cross-resistance patterns and correlations in HIV-1
38. Unblocking of chain-terminated primer by HIV-1 RT through a nucleotide-dependent mechanism
39. Rapid in vitro selection of HIV type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of RT
40. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
41. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy: Trilège
42. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virologic evaluation of the AVANTI 2 and AVANTI 3 studies
43. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir
44. The role of abacavir in antiretroviral therapy-experienced patients: Results from a randomised, double blind trial: CNA3002 European Study Team
45. Multiple concurrent RT and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
46. Highly drug resistant HIV-1 isolates are cross-resistant to many of the current anti-HIV compounds in clinical development
47. Lamivudine resistance in HIV-1 RT involves steric hindrance with beta-branched amino acids
48. Phase I/II study of 3TC in HIV-positive, asymptomatic or mild AIDS-related complex patients: Sustained reduction in viral markers
49. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
50. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the RT enzyme
51. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential
52. Lamivudine resistance of HIV-1 does not delay development of resistance to non-nucleoside HIV-1 specific RT inhibitors as compared with wild type HIV-1
53. Potential mechanisms for sustained antiretroviral efficacy of AZT-3TC combination therapy
54. Emergence of dual resistance to zidovudine and lamivudine in HIV-1 infected patients treated with zidovudine plus lamivudine as initial therapy
55. A novel polymorphism at codon 333 of HIV-1 RT can facilitate dual resistance to zidovudine and lamivudine
56. Prevalence of the codon 333 resistance genotype in naive and pre-treated patients in Spain
57. The M184V mutation in the RT of HIV type 1 impairs rescue of chain-terminated DNA synthesis
58. Lamivudine in combination with zidovudine, stavudine or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial (ACTG 306)
59. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy
60. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 RT
61. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors
62. Combination therapy with zidovudine and didanosine selects for drug-resistant HIV-1 strains with unique patterns of pol gene mutations
63. Emergence of HIV-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
64. Multiple dideoxynucleoside analogue-resistant HIV-1 strains isolated from patients from different European countries
65. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues
66. Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues
67. Genotypic and phenotypic changes during culture of a multinucleoside-resistant HIV-1 strain in the presence and absence of additional RT inhibitors
68. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir
69. Structure of a covalently trapped catalytic complex of HIV-1 RT: Implications for drug resistance
70. A 6-basepair insert in the RT gene of HIV-1 confers resistance to multiple nucleoside inhibitors
71. A family of insertion mutations between codons 67 and 70 of HIV-1 RT confer multinucleoside analog resistance
72. Multidrug resistance genotypes (insertions in the b3-b4 finger subdomain and MDR mutations) of HIV-1 RT from extensively treated patients: Incidence and association with other resistance mutations
73. Insertion of two amino acids combined with changes in RT containing tyrosine 215 of HIV-1 resistant to multiple nucleoside analogs
74. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance
75. Identification of a mutation at codon 65 in the IKKK motif of RT that encodes HIV resistance to ddC and 3TC
76. Novel mutation (V75T) in HIV-1 RT confers resistance to d4T in cell culture
77. Stavudine resistance: An update on susceptibility following prolonged therapy
78. A novel HIV-1 RT mutational pattern confers phenotypic lamivudine resistance in the absence of mutation M184V
79. Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pre-treated HIV-infected individuals
80. Antiretroviral resistance mutations (revised April 2001)
81. Puting the brakes on drug approval: Adefovir
82. Novel mutation (K70E) in HIV-1 RT confers decreased susceptibility to 9-[2-(phosphonomethoxy)-ethyl] adenine in vitro
83. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
84. Identification of a mutation of codon 65 in the IKKK motif of RT that encodes HIV resistance to 2′,3′-dideoxycytine and 2′,3′-dideoxy-3′-thiacytidine
85. Combination of mutations in HIV-1 RT required for resistance to the carbocyclic nucleoside 1592U89
86. Mutations in the pol gene of HIV-1 in infected patients receiving didanosine and hydroxyurea combination therapy
87. K65R mutation in HIV-1 RT encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
88. HIV-1 expressing the lamivudine-associated M184V mutation in RT shows increased susceptibility to adefovir and decreased replication capability in vitro
89. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
90. Anti-HIV activity profile of tenofovir (PMPA) against a panel of nucleoside-resistant clinical samples
91. Comparison of nucleoside and nucleotide RT inhibitor removal by ATP-dependent chain terminator-removal mechanism
92. Crystal structure of HIV-1 RT with template-primer terminated with the acyclic nucleotide RT inhibitor tenofovir
93. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
94. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
95. Specific inhibition of the RT of HIV-1 and the chimeric enzymes of HIV type 1 and 2 by non-nucleoside inhibitors
96. Use of chimeric HIV types 1 and 2 RT for structure-function analysis and for mapping susceptibility to non-nucleoside inhibitors
97. Susceptibility of HIV-1 group O isolates to antiretroviral agents: In vitro genotypic and phenotypic analyses
98. Reduced susceptibility of HIV-1 from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
99. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
100. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients
101. DMP-266: A novel, highly potent non-nucleoside inhibitor of the HIV-1 RT
102. Non nucleoside reverse transcriptase inhibitors
103. Delavirdine in combination with zidovudine in treatment of HIV-1 infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial
104. NNRTI resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
105. Mutations in retroviral genes associated with drug resistance
106. Efavirenz and adefovir based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
107. Can early failure with nevirapine be rescued with efavirenz
108. HIV-1 mutations selected in patients failing efavirenz combination therapy
109. A proline-tohistidine substitution at position 225 of HIV-1 RT sensitizes HIV-1 RT to BHAP U-90152
110. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication
111. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of HIV type 1 reverse transcriptase
112. Interactions between drug resistance mutations in HIV-1 RT
113. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in 3TC-experienced patients: Results of ACTG 370
114. Nonnucleoside reverse transcriptase inhibitors